Human monoclonal antibodies for discovery, therapy, and vaccine acceleration
2019; Elsevier BV; Volume: 59; Linguagem: Inglês
10.1016/j.coi.2019.07.005
ISSN1879-0372
AutoresEmanuele Andreano, Anja Seubert, Rino Rappuoli,
Tópico(s)Viral Infections and Immunology Research
ResumoScreening of single B cells from convalescent or vaccinated people allows the discovery of novel targets for infectious diseases and rapid production of engineered human monoclonal antibodies (mAbs) that can prevent or control infections by passive immunization. Here we propose that the development of human mAbs can also significantly accelerate vaccine development by anticipating some of the key biological and regulatory questions.
Referência(s)